Aerovate Newsroom

Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift

TipRanksNov 13 12:45

Aerovate | 10-Q: Q3 2024 Earnings Report

SECNov 13 05:46 · Announcements

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 11 19:00

M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More

Seeking AlphaNov 3 03:34

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaNov 1 00:34

Express News | Aerovate Therapeutics - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Jade Termination Fee of $2.3 Mln

BreakingsOct 31 21:34

Express News | Aerovate Therapeutics - Exchange Ratio Assumes Valuation for Aerovate of $8.0 Million and Valuation for Jade of $175.0 Mln

BreakingsOct 31 21:33

Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

BusinesswireOct 31 21:31

Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment

Dow JonesOct 31 20:40

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

Jade BiosciencesOct 31 20:38

Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaOct 31 19:25

Aerovate: Resulting Entity Will Focus on Advancing Jade's Portfolio of Novel Biologics >AVTE

Dow JonesOct 31 19:17

Express News | Aerovate Therapeutics Inc - Stockholders to Own 1.6% of Combined Company

BreakingsOct 31 19:01

Express News | Aerovate Therapeutics Inc - Jade Secures $300 Million in Private Investment

BreakingsOct 31 19:01

Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending

BenzingaOct 31 18:55

Aerovate Therapeutics Board Member Maha Katabi Resigns

TipRanksOct 11 05:28

12 Health Care Stocks Moving In Tuesday's After-Market Session

BenzingaOct 2 04:31

Oppenheimer Downgrades Aerovate(AVTE.US) to Hold Rating, Cuts Target Price to $3

Oppenheimer analyst Andreas Argyrides downgrades $Aerovate(AVTE.US)$ to a hold rating, and adjusts the target price from $41 to $3.According to TipRanks data, the analyst has a success rate of 44.7%

Futu NewsAug 13 20:33 · Ratings

Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)

TipRanksAug 13 20:01 · Ratings

Aerovate | 10-Q: Q2 2024 Earnings Report

SECAug 13 04:36 · Announcements